Cargando…

Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak

BACKGROUND: The Coronavirus pandemic outbreak in 2019 and the saturation of healthcare system led to an increased use of digital tools for surveillance. In this study we described our experience using telemedicine to follow-up on patients with intraductal papillary mucinous neoplasms during the COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Farguell, J., Holguin, V., González, C., Gil, I., Arrocha, C., Landi, F., Vaquero, E., Gines, A., Fillat, C., Ausania, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468315/
https://www.ncbi.nlm.nih.gov/pubmed/36272774
http://dx.doi.org/10.1016/j.surg.2022.09.005
_version_ 1784788382062215168
author Farguell, J.
Holguin, V.
González, C.
Gil, I.
Arrocha, C.
Landi, F.
Vaquero, E.
Gines, A.
Fillat, C.
Ausania, F.
author_facet Farguell, J.
Holguin, V.
González, C.
Gil, I.
Arrocha, C.
Landi, F.
Vaquero, E.
Gines, A.
Fillat, C.
Ausania, F.
author_sort Farguell, J.
collection PubMed
description BACKGROUND: The Coronavirus pandemic outbreak in 2019 and the saturation of healthcare system led to an increased use of digital tools for surveillance. In this study we described our experience using telemedicine to follow-up on patients with intraductal papillary mucinous neoplasms during the COVID-19 era and analyze those factors associated to patients’ satisfaction. METHODS: This 1-year retrospective observational study enrolled patients with intraductal papillary mucinous neoplasms followed-up by telemedicine during COVID-19 outbreak. Patients with high-risk features needing on-site physical examination or declining remote follow-up were excluded. A 13-question survey was conducted; demographic, geographic, and employment information was collected. Univariate and multivariate analyses were performed to evaluate those factors associated to patients’ satisfaction. RESULTS: Out of 287, a total of 177 patients with intraductal papillary mucinous neoplasms were included: the mean age was 69 (44–87) years and the male/female ratio was 0.78. A total of 80 (45.2%) patients had previously experienced abdominal pain. Most patients (85.3%) were satisfied with telemedicine: at univariate analysis, age ≥70 years (P = .007), retirement (P = .001), and absence of previous abdominal pain (P = .05) were significantly associated with patient satisfaction. At multivariate analysis, the absence of previous abdominal pain was the only factor independently associated with patient satisfaction (odds ratio 5.964, 95% confidence interval 2.21–16.11, P < .001). CONCLUSION: Telemedicine allows a new follow-up strategy that can be used in selected patients with intraductal papillary mucinous neoplasms. The absence of previous abdominal pain is associated with patient satisfaction during follow-up. Further studies are needed to evaluate safety of remote follow-up in patients with intraductal papillary mucinous neoplasms.
format Online
Article
Text
id pubmed-9468315
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-94683152022-09-13 Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak Farguell, J. Holguin, V. González, C. Gil, I. Arrocha, C. Landi, F. Vaquero, E. Gines, A. Fillat, C. Ausania, F. Surgery Covid-19 BACKGROUND: The Coronavirus pandemic outbreak in 2019 and the saturation of healthcare system led to an increased use of digital tools for surveillance. In this study we described our experience using telemedicine to follow-up on patients with intraductal papillary mucinous neoplasms during the COVID-19 era and analyze those factors associated to patients’ satisfaction. METHODS: This 1-year retrospective observational study enrolled patients with intraductal papillary mucinous neoplasms followed-up by telemedicine during COVID-19 outbreak. Patients with high-risk features needing on-site physical examination or declining remote follow-up were excluded. A 13-question survey was conducted; demographic, geographic, and employment information was collected. Univariate and multivariate analyses were performed to evaluate those factors associated to patients’ satisfaction. RESULTS: Out of 287, a total of 177 patients with intraductal papillary mucinous neoplasms were included: the mean age was 69 (44–87) years and the male/female ratio was 0.78. A total of 80 (45.2%) patients had previously experienced abdominal pain. Most patients (85.3%) were satisfied with telemedicine: at univariate analysis, age ≥70 years (P = .007), retirement (P = .001), and absence of previous abdominal pain (P = .05) were significantly associated with patient satisfaction. At multivariate analysis, the absence of previous abdominal pain was the only factor independently associated with patient satisfaction (odds ratio 5.964, 95% confidence interval 2.21–16.11, P < .001). CONCLUSION: Telemedicine allows a new follow-up strategy that can be used in selected patients with intraductal papillary mucinous neoplasms. The absence of previous abdominal pain is associated with patient satisfaction during follow-up. Further studies are needed to evaluate safety of remote follow-up in patients with intraductal papillary mucinous neoplasms. Elsevier Inc. 2022-12 2022-09-13 /pmc/articles/PMC9468315/ /pubmed/36272774 http://dx.doi.org/10.1016/j.surg.2022.09.005 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Covid-19
Farguell, J.
Holguin, V.
González, C.
Gil, I.
Arrocha, C.
Landi, F.
Vaquero, E.
Gines, A.
Fillat, C.
Ausania, F.
Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak
title Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak
title_full Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak
title_fullStr Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak
title_full_unstemmed Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak
title_short Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak
title_sort telemedicine and intraductal papillary mucinous neoplasms: analysis of a new follow-up strategy during covid-19 outbreak
topic Covid-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468315/
https://www.ncbi.nlm.nih.gov/pubmed/36272774
http://dx.doi.org/10.1016/j.surg.2022.09.005
work_keys_str_mv AT farguellj telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak
AT holguinv telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak
AT gonzalezc telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak
AT gili telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak
AT arrochac telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak
AT landif telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak
AT vaqueroe telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak
AT ginesa telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak
AT fillatc telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak
AT ausaniaf telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak